<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912782</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00014859</org_study_id>
    <nct_id>NCT00912782</nct_id>
  </id_info>
  <brief_title>Vitamin D and Arteriovenous Fistulae</brief_title>
  <official_title>Impact of Vitamin D on Arteriovenous Fistulae Maturation Among ESRD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients requiring hemodialysis following kidney failure need a form of dialysis vascular
      access in order to undergo the dialysis procedure. Dialysis vascular access dysfunction is an
      enormous clinical problem. While the best form of vascular access is the arteriovenous
      fistula (AVF), its primary problem is early, aggressive cellular ingrowth that leads to poor
      maturation of the vessel, preventing its use for dialysis. Strategies to prevent AVF failure
      are needed.

      Vitamin D is a hormone present in all human bodies and is important for good bone formation
      and immune function. There is new information that links vitamin D to the function of our
      veins and arteries, which are used in the creation of an arteriovenous fistulae. Our bodies
      can make vitamin D and can also get vitamin D from our diet. However, a majority of patients
      with chronic kidney disease and end-stage renal disease (ESRD) have low vitamin D levels
      (vitamin D deficiency). There are several benefits to correcting low vitamin D levels,
      however, it is not know whether correcting low vitamin D in the body will lead to better
      function of the vein and artery used for arteriovenous fistulae creation. The main goal of
      this pilot study is to examine the role of vitamin D supplementation on AVF maturation and
      useability for dialysis. Study results will be used to develop larger studies to examine the
      specific effect that vitamin D supplementation has on the vessels used for AVF creation and
      whether vitamin D promotes AVF maturation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemodialysis vascular access dysfunction is a major source of morbidity and cost among ESRD
      patients, accounting for up to 25% of all hospital stays, and 50% of all costs within the
      first year of initiating dialysis.The AVF provides higher blood flow rates, fewer thrombotic
      and infectious complications, and lower morbidity and cost compared with prosthetic grafts or
      central venous catheters.However,up to 50% of newly created AVF's fail to mature sufficiently
      for chronic hemodialysis use. Clearly, determining factors predictive of poor AVF maturation
      are important from both patient care and health policy perspectives and are worthy of
      investigation.

      Vitamin D has antiproliferative, antioxidant and antiangiogenic properties. The observed
      association of vitamin D deficiency and increased risk of cardiovascular and peripheral
      vascular disease may extend to the vasculature used in the creation of an AVF.

      As renal function worsens, patients with chronic kidney disease (CKD) produce less vitamin D,
      due to impaired renal conversion of 25-hydroxy- to 1,25-dihydroxyvitamin D by declining renal
      1-alpha hydroxylase. As a result, at the time of dialysis initiation,78%-90% of ESRD patients
      are vitamin D deficient. Until recently, vitamin D deficiency among CKD and ESRD patients was
      only treated if hyperparathyroidism was present, however, more attention is now paid to
      nutritional vitamin D deficiency given its association with a range of comorbid
      conditions.Furthermore, 1,25-dihydroxyvitamin D and its analogue compounds are associated
      with improved survival in the CKD and ESRD populations. We believe that the observed benefits
      of vitamin D may improve AVF maturation among a population in which vitamin D deficiency is
      highly prevalent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arteriovenous Fistulae Maturation</measure>
    <time_frame>6 months</time_frame>
    <description>Maturation of an AVF is the ability to stick the AVF with two large bore needles at â‰¥ 6 consecutive dialysis sessions, and achievement of an AVF blood flow &gt;300 ml/min, assessed at six months following AVF creation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>25-hydroxyvitamin D and Serum Calcium</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo one time per week for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D 200,000 IU per week for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 200,000 IU once a week for 3 weeks</description>
    <arm_group_label>Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo one time per week for 3 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients with patients with end-stage renal disease (ESRD) who are suitable candidates
             for AVF creation (as assessed by pre-operative vein mapping) and plan to undergo AVF
             creation are eligible to participate

          -  Study subjects must agree to participate in the study and provide written informed
             consent

          -  Age: Study subjects must be &gt; 18 years old

          -  Sites: Emory University affiliated hospitals (including Emory University Hospital,
             Emory Midtown Hospital, Grady Memorial Hospital) and Emory University affiliated
             outpatient dialysis units

          -  Informed consent requirements: All study subjects must agree to participate in the
             study and provide written informed consent.

        Exclusion Criteria

          -  Age &lt; 18 years

          -  Patients with a corrected serum calcium &gt; 10.5 mg/dL within 4 weeks of study screening

          -  Current intake of &gt; 2000 IU per day of Vitamin D3

          -  Subjects unable to provide informed consent or who plan to relocate outside of Atlanta
             during the study duration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haimanot Wasse, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <results_first_submitted>November 2, 2013</results_first_submitted>
  <results_first_submitted_qc>June 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2014</results_first_posted>
  <last_update_submitted>June 2, 2014</last_update_submitted>
  <last_update_submitted_qc>June 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Monnie Wasse MD, MPH, FASN</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>ESRD</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Arteriovenous Fistulae</keyword>
  <keyword>Dialysis Vascular Access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>107 Assessed for Eligibility with 55 Excluded for declining to participate (12), not meeting criteria (41), and other reasons (6) leaving 52 patients randomly assigned for the study. Some individuals were counted as having more than two reasons to be excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo one time per week for 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>Cholecalciferol</title>
          <description>Vitamin D 200,000 IU per week for 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive vascular access type</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocated before study completion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo one time per week for 3 weeks</description>
        </group>
        <group group_id="B2">
          <title>Cholecalciferol</title>
          <description>Vitamin D 200,000 IU per week for 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="14.9"/>
                    <measurement group_id="B2" value="49.9" spread="10.9"/>
                    <measurement group_id="B3" value="51.1" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Arteriovenous Fistulae Maturation</title>
        <description>Maturation of an AVF is the ability to stick the AVF with two large bore needles at â‰¥ 6 consecutive dialysis sessions, and achievement of an AVF blood flow &gt;300 ml/min, assessed at six months following AVF creation.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo one time per week for 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol</title>
            <description>Vitamin D 200,000 IU per week for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Arteriovenous Fistulae Maturation</title>
          <description>Maturation of an AVF is the ability to stick the AVF with two large bore needles at â‰¥ 6 consecutive dialysis sessions, and achievement of an AVF blood flow &gt;300 ml/min, assessed at six months following AVF creation.</description>
          <units>percentage of group</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>25-hydroxyvitamin D and Serum Calcium</title>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo one time per week for 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol</title>
            <description>Vitamin D 200,000 IU per week for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>25-hydroxyvitamin D and Serum Calcium</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum 25 (OH) D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="7.4"/>
                    <measurement group_id="O2" value="53.4" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="0.6"/>
                    <measurement group_id="O2" value="8.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo one time per week for 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>Cholecalciferol</title>
          <description>Vitamin D 200,000 IU per week for 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Monnie Wasse MD/MPH / Associate Professor of Medicine</name_or_title>
      <organization>Emory University</organization>
      <phone>404-727-1598</phone>
      <email>hwasse@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

